Therefore, anti-PD-1/PD-L1 antibodies or PD-1/PD-L1 inhibitors have been tested for their therapeutic response in many cancers, including HNSCC, where two (pembrolizumab, nivolumab) are now FDA approved for recurrent or metastatic disease. This evidence concerns the gene PDCD1 and metastatic neoplasm.